Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider

Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider

Bibliographic Details
Main Authors: Patrick M. Honore, Leonel Barreto Gutierrez, Luc Kugener, Sebastien Redant, Rachid Attou, Andrea Gallerani, David De Bels
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Critical Care
Online Access:http://link.springer.com/article/10.1186/s13054-020-03294-7

Internet

http://link.springer.com/article/10.1186/s13054-020-03294-7

Similar Items